Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This study proposes to:
1. Characterize the impact of oral vancomycin on C. difficile loads after end of treatment
compared to a placebo group.
2. Determine the effect of oral vancomycin on structural and functional microbiome changes
after end of treatment compared to a placebo group.
3. Characterize the impact of oral vancomycin against a placebo group on the daily
frequency of loose stools by the end of treatment.